Physician profile
Peter R Ennever
NPI 1154372738
$6,665.61
in general payments reported to CMS, 2019-2025
45 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $327 · 2021: $192 · 2023: $222 · 2024: $2,316 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.25 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $290.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,829.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $535.76 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $522.34 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| Pfizer INC. | $454.06 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $316.74 | 2019-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $271.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $248.23 | 2019-2024 | Reblozyl, Pomalyst |
| Incyte Corporation | $216.19 | 2019-2025 | Jakafi, Monjuvi |
| Genzyme Corporation | $153.06 | 2019-2025 | |
| Eisai INC. | $148.84 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $147.58 | 2019-2024 | Ultomiris |
| Gilead Sciences, INC. | $128.08 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $119.25 | 2019-2025 | Fruzaqla |
| Array Biopharma INC | $113.83 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $99.49 | 2019-2025 | Cabometyx |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ennever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.